Takeda: Essential Hypertension trials

The registry lists 23 Essential Hypertension studies with Takeda as lead sponsor. 0 are open to participants now and 18 have results posted.

Phase 2 3Phase 3 18Phase 4 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in AsiaCompletedNCT02517866Phase 4Results posted
• Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With HypertensionCompletedNCT02480764Phase 3Results posted
• A Phase III Long-term Study of TAK-536TCH in Participants With Essential HypertensionCompletedNCT02277691Phase 3Results posted
• A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-RCompletedNCT02079805Phase 4Results posted
• A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil AloneCompletedNCT01456169Phase 3Results posted
• Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.CompletedNCT01033071Phase 3Results posted
• Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential HypertensionCompletedNCT00996281Phase 3Results posted
• Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe HypertensionCompletedNCT00846365Phase 3Results posted
• Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe HypertensionCompletedNCT00818883Phase 3Results posted
• Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential HypertensionCompletedNCT00760214Phase 3Results posted
• An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.CompletedNCT00696436Phase 3Results posted
• A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential HypertensionCompletedNCT00696384Phase 3Results posted
• Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential HypertensionCompletedNCT00696241Phase 3Results posted
• One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential HypertensionCompletedNCT00695955Phase 3Results posted
• Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential HypertensionCompletedNCT00591773Phase 3Results posted
• Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential HypertensionCompletedNCT00591578Phase 3Results posted
• Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential HypertensionCompletedNCT00591266Phase 3Results posted
• Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential HypertensionCompletedNCT00591253Phase 3Results posted
• An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential HypertensionWithdrawnNCT02969265Phase 3
• A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.WithdrawnNCT02400775Phase 4
• Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.CompletedNCT02072330Phase 2/3
• Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential HypertensionCompletedNCT01289132Phase 2
• Efficacy and Safety of Azilsartan in Subjects With Essential HypertensionCompletedNCT00759551Phase 2